Press Releases

Cannasat Therapeutics to Commence Phase 1 Study of CAT 310, a Potential Treatment for Neuropathic Pain, August 23, 2021

TORONTO – Cannasat Therapeutics Inc. ("Cannasat") (TSX-V: CTH), announced today that Health Canada has approved Cannasat’s clinical trial application for a Phase 1 clinical study with its lead product, CAT 310. Cannasat received a “No Objection Letter” from Health Canada to conduct this clinical study for its first cannabinoid based product that is designed to help manage neuropathic pain and other disorders.

The cannabinoid class of drugs may provide significant benefit to patients by themselves or in conjunction with other classes of approved drugs, such as opiates and anticonvulsants, for the treatment of neuropathic pain.

This Phase 1 trial is a randomized, single dose, crossover study comparing two different formulations of the drug in normal healthy male volunteers. The primary objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of the CAT 310 prototypes. Enrolment in Canada for this trial is expected to begin in early October 2007.

David Hill, CEO of Cannasat, said, "We are very pleased that Health Canada has expeditiously approved our clinical trial application. This significant milestone will transform the company from a pre-clinical research company to a Phase 1 pharmaceutical company engaged in developing safe and effective cannabinoid products that target unmet medical needs.”

Neuropathic pain is associated with nerve damage and can be an especially difficult to treat condition, often requiring the use of strong narcotics that can cause serious adverse effects. This condition is can be caused by many common diseases such as diabetes, herpes zoster, HIV/AIDS, multiple sclerosis, and other causes of chronic pain. Most patients require treatment with multiple drugs and often achieve only partial relief. It is estimated that over 15 million people suffer from some variety of neuropathic pain in North America and Europe.


About Cannasat Therapeutics

Founded in 2004, Cannasat is an early stage pharmaceutical research and development company. Cannasat is developing cannabinoid-based pharmaceutical products using proprietary formulation and drug delivery technologies. Cannabinoids have broad therapeutic applications which are believed to include the treatment of neuropathic pain, chronic pain, depression, anxiety and movement disorders. More information about Cannasat (TSX-V: CTH) is available at


Contact Information

Cannasat Therapeutics Inc.
Andrew Williams
Chief Operating Officer
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]


Forward Looking Statements

Certain statements in this release may constitute forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors, which may cause actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.


The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on